Reed Jobs would rather talk about curing cancer than his last name

Reed Jobs is a refreshing presence in the biotechnology arena. With an engaging personality, he often uses humor and video game analogies to discuss his work. While he is the son of the late Steve Jobs, he prefers to focus on his current mission rather than his famous lineage. During a recent video call, he humorously dismissed the notion of using a MacBook, expressing a clear passion for his endeavors. In 2023, Reed launched Yosemite, a venture capital firm dedicated to oncology. His goal is to develop biotech companies derived from pioneering academic research, utilizing a blend of philanthropy and traditional venture funding. Three years into this journey, Jobs is eager to elevate Yosemite into a formidable player in the industry, especially as the intersection of AI and drug development opens new avenues. Among his proudest achievements is Azalea, a company that emerged from a grant to Jennifer Doudna's lab and is currently in clinical trials. Another noteworthy project is Quarry, founded in collaboration with Craig Crews to advance a therapeutic technique known as induced proximity, which allows drugs to effectively target harmful proteins by directing them to the cell's degradation system. When Yosemite was first introduced at TechCrunch Disrupt, the biotech sector was grappling with the aftermath of the pandemic. Now, with a growing team of 17 and a slew of blockbuster drugs facing patent expiration, the landscape has shifted dramatically. AI has evolved from a mere curiosity to a central element of Yosemite's operations. In a recent discussion, Jobs provided insights about the firm’s trajectory and future plans. "We're experiencing significant momentum," he noted, emphasizing the unique nature of Yosemite, which focuses exclusively on oncology and emphasizes creating its own companies. Approximately one-third of the firm’s new $350 million fund is earmarked for developing in-house projects, with the remainder allocated to established companies. This model allows Yosemite to de-risk early-stage ideas using philanthropic funding. The changing dynamics in biotech investment have also caught Jobs's attention. The past three years have seen interest rates stabilize and pharmaceutical companies gearing up for a historic patent cliff, leading to increased acquisition activity in the sector. Jobs also voiced concerns regarding federal funding for research, particularly referencing attempts to cut NIH budgets. Despite these challenges, he noted bipartisan support for maintaining funding levels, advocating for a significant increase to $100 billion to better address inflation and research needs. AI's role in healthcare delivery is another area where Jobs sees tremendous potential. He pointed out that many American hospitals still rely on outdated technology, making them prime candidates for AI integration. In clinical trials, AI could significantly streamline patient recruitment, saving both time and money. When discussing drug discovery, Jobs expressed enthusiasm for AI's transformative power, stating that it accelerates processes, enabling researchers to explore previously inaccessible areas of the genome. Noteworthy advancements suggest that targets once deemed undruggable, such as the p53 tumor suppressor gene, may now be within reach. With nearly 25 companies in Yosemite's portfolio, Jobs acknowledged that scientific failure is part of the process. He encouraged founders in the biotech space to remain adaptable and to view partnerships with pharmaceutical companies as evolving challenges. As he reflects on his journey with Yosemite, Jobs is surprised by how quickly the industry is evolving, spurred by new insights and technologies. He remains committed to exploring innovative solutions in oncology and is excited about the opportunities that lie ahead in combating cancer and other diseases.